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This study demonstrates the effectiveness of a novel self-adjuvanting vaccine delivery system for multiple
different synthetic peptide immunogens by use of lipid core peptide (LCP) technology. An LCP formulation
incorporating two different protective epitopes of the surface antiphagocytic M protein of group A streptococci
(GAS)—the causative agents of rheumatic fever and subsequent rheumatic heart disease—was tested in a
murine parenteral immunization and GAS challenge model. Mice were immunized with the LCP-GAS formu-
lation, which contains an M protein amino-terminal type-specific peptide sequence (8830) in combination with
a conserved non-host-cross-reactive carboxy-terminal C-region peptide sequence (J8) of the M protein. Our
data demonstrated immunogenicity of the LCP-8830-J8 formulation in B10.BR mice when coadministered in
complete Freund’s adjuvant and in the absence of a conventional adjuvant. In both cases, immunization led to
induction of high-titer GAS peptide-specific serum immunoglobulin G antibody responses and induction of
highly opsonic antibodies that did not cross-react with human heart tissue proteins. Moreover, mice were
completely protected from GAS infection when immunized with LCP-8830-J8 in the presence or absence of a
conventional adjuvant. Mice were not protected, however, following immunization with an LCP formulation
containing a control peptide from a Schistosoma sp. These data support the potential of LCP technology in the
development of novel self-adjuvanting multi-antigen component vaccines and point to the potential application
of this system in the development of human vaccines against infectious diseases.
To induce effective immunostimulation and protective im-
munity, vaccines comprising a particular antigen or fragment
thereof require a suitable adjuvant in addition to a carrier
system. This is a critical issue with newer-generation vaccines
such as subunit, recombinant, and synthetic vaccines, which,
despite containing purer antigens, tend to be poorly immuno-
genic compared to live attenuated vaccine formulations (3, 43).
The efficacy of conventional vaccine formulations, adminis-
tered parenterally and mucosally in experimental animal mod-
els, has required the use of adjuvants such as complete
Freund’s adjuvant (CFA) (7) and cholera toxin (20), respec-
tively, which are not suitable for use in humans due to their
toxicity. Current vaccine formulations licensed for human use
mainly contain alum-based adjuvants (such as aluminum hy-
droxide or aluminum phosphate) (18). This limited choice of
adjuvants for human vaccination reflects a compromise be-
tween a requirement for adjuvanticity and an acceptably low
level of toxicity.
Development of novel human vaccine delivery strategies for
both existing and reemerging infections faces significant hur-
dles, particularly with regard to development of safe, effective,
nontoxic adjuvants, in addition to the number of antigens that
can be included in any one formulation, as multiple antigens
may be required for successful vaccination against certain
pathogens to provide broad coverage. Research is now focused
on the development of vaccine adjuvants with improved im-
munogenicity, reduced toxicity, universal efficacy, and the po-
tential for delivery via other routes, such as mucosal delivery
for vaccination against many pathogens that infect mucosal
surfaces. Recent advances in vaccine immunology have in-
cluded the development of sophisticated antigen delivery sys-
tems, especially those based on synthetic peptide immunogens
(23, 33), and the development of alternative adjuvants for
vaccine delivery, including genetically manipulated bacterial
toxins, monophosphoryl lipid A, immunostimulatory com-
plexes, proteosomes (outer membrane proteins of Neisseria
meningitidis), live commensal bacteria and bacterial particles,
and novel lipid-containing compounds (reviewed in references
3, 18, 25, and 33).
The development of novel synthetic adjuvants offers the
possibility of vaccine delivery without the need for additional
adjuvant. Synthetic lipid-based compounds using various li-
popeptides (11, 24, 28, 39, 40) or, as described by Toth and
colleagues (45), using lipid core peptide (LCP) technology
provide an attractive alternative for vaccine delivery. The LCP
system incorporates lipoamino acids coupled to a polylysine
core containing up to two different antigenic peptides (45) (see
Fig. 1) and is uniquely designed to incorporate antigen, carrier,
and adjuvant in a single molecular entity. The LCP system
essentially combines the multiple antigen peptide (MAP) and
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tripalmitoyl-S-glyceryl cysteine (Pam3Cys) systems. MAPs in-
corporate peptides coupled onto a polylysine core; significantly
higher antibody titers have been obtained upon immunization
with MAPs than by immunization with carrier protein-conju-
gated peptides in the presence of adjuvant (44). The Pam3Cys
system utilizes a synthetic analog of the N-terminal moiety of
bacterial lipoprotein from Escherichia coli as a lipid anchor
moiety (26). When covalently linked to a peptide, tetrameric
forms of a MAP, or polyoxime constructs, Pam3Cys lipopep-
tide compounds have been found to be potent immunogens
with self-adjuvanting properties, eliciting humoral and cellular
responses irrespective of the route of administration (27, 29,
30, 47). Most importantly, lipopeptides represent potentially
safe vaccines for human application (1).
LCP-based vaccine candidates incorporating variable do-
mains of Chlamydia trachomatis outer membrane protein have
been shown to significantly enhance peptide immunogenicity
over that of peptide monomers given alone in adjuvant (48),
and an LCP compound incorporating a foot-and-mouth dis-
ease viral peptide was immunogenic, resulting in induction of
anti-peptide antibodies in the absence of additional adjuvant
(46). Recently, we investigated the LCP system as a vaccine
delivery strategy for group A streptococci (GAS) (31), the
causative agents of rheumatic fever (RF) and subsequent rheu-
matic heart disease (RHD) (4, 12). RF and RHD are a major
health concern in developing countries and indigenous popu-
lations worldwide, but especially among Australian aboriginals,
who suffer the highest disease rates (9). The bacterial surface
anti-phagocytic M protein (12), a major GAS vaccine candi-
date, was the targeted antigen. Protective immunity to GAS
infection has been associated with the presence of type-specific
opsonic antibodies against M protein (12), although opsonic
antibodies specific to the carboxy-terminal conserved C region
have been demonstrated in humans (5) and mice immunized
with C-region peptides (37) and are also important in eliciting
protective immunity to GAS (6). Mice immunized parenter-
ally, in the absence of a conventional adjuvant, with an LCP
formulation containing a protective C-region determinant of
the GAS M protein elicited high-titer, heterologous opsonic
antibodies that did not cross-react with human heart tissue
proteins (31), indicating the potential of such a vaccine for
inducing broadly protective immune responses.
This study has further investigated the potential of LCP
technology in the development of a novel self-adjuvanting
multi-antigen component vaccine delivery system by using a
murine model of parenteral immunization and GAS challenge.
Mice were immunized with an LCP formulation incorporating
two different protective epitopes of the GAS M protein—an
amino-terminal type-specific peptide sequence (6) in conjunc-
tion with a conserved carboxy-terminal C-region peptide se-
quence (19) designed to lack a human heart-cross-reactive
T-cell epitope (36)—prior to assessment of immunogenicity,
induction of serum opsonic antibodies, and protection against
GAS infection upon challenge.
MATERIALS AND METHODS
GAS peptides. The sequence of the 8830 peptide, corresponding to the type-
specific amino-terminal region of the M protein of GAS strain 8830, residues 1
to 20, is DNGKAIYERARERALQELGPC. The sequence of the J8 peptide is
QAEDKVKQSREAKKQVEKALKQLEDKVQ, corresponding to amino acid
residues 344 to 355, inclusive of the conserved carboxy-terminal C region, of the
M protein of the M1 GAS strain. The J8 peptide used is a chimeric peptide that
contains 12 amino acids from the M protein C region (boldfaced in the sequence)
and is flanked by yeast-derived GCN4 sequences, which was necessary in order
to maintain the correct helical folding and conformational structure of the
peptide (38).
Synthesis and purification of peptides. Peptides were synthesised by manual
solid-phase peptide synthesis using Boc (tert-butoxycarbonyl) chemistry as de-
scribed by Schno¨lzer et al. (41). Following synthesis, peptides were removed from
the resin by hydrofluoric acid cleavage; the crude peptides were precipitated with
ice-cold ethyl ether, filtered, and redissolved in 50% acetonitrile; and the resin
was removed by filtration. The reaction mixture was lyophilized. Peptide purifi-
cation was carried out on a Waters high-pressure liquid chromatography (HPLC)
system (model 600 controller, 490 E UV detector, 60 F pump) using a prepar-
ative Vydac protein and peptide C18 column (2 by 25 cm). Separation was
achieved with a solvent gradient beginning with 0% acetonitrile and increasing
constantly to 90% acetonitrile for 40 min at a constant flow of 12 ml per min.
Peptides were detected at 230 nm. Analytical reversed-phase HPLC was per-
formed on a Shimadzu instrument (LC-10AT liquid chromatograph, SCL-10A
system controller, SPD-6A UV detector, and SIL-6b autoinjector with SCL-6B
system controller) using a Vydac C18 column (5-m pore size; 0.46 by 25 cm).
Separation was achieved with a solvent gradient beginning with 0% acetonitrile
and increasing constantly to 90% acetonitrile for 30 min at a constant flow of 1
ml per min. Peptides were detected at 214 nm.
Synthesis of the LCP-8830-J8 (LCP-GAS) formulation. Boc-L-amino acids and
4-methylbenzhydrylamine (MBHA) resin were purchased from Novabiochem
(La¨ufelfingen, Switzerland). Racemic lipoamino acids were synthesized with Boc
protection according to the procedures of Gibbons et al. (17). For synthesis of
the LCP-8830-J8 formulation (also referred to as LCP-GAS) containing two
copies each of the 8830 GAS peptide and the J8 GAS peptide, preactivated
Boc-Gly-OH was coupled to the MBHA resin (0.67 mmol/g) in the first step. The
next two cycles were carried out with Boc-lipoamino acids containing 8 carbon
FIG. 1. Chemical structure of the LCP-8830-J8 (LCP-GAS) formulation. LCP-8830-J8 was synthesized containing three 2-amino-octanoic
lipoamino acids (shown as branched alkyl side chains) attached to a polylysine core, with two copies each of the 8830 and J8 GAS peptides attached
to the amino groups of each lysine. Glycine spacers were employed, one between the resin and the first lipoamino acid and one between the second
and third lipoamino acids. In LCP-8830-J8, P1 stands for the 8830 GAS peptide (DNGKAIYERARERALQELGPC) and P2 stands for the J8
GAS peptide (QAEDKVKQSREAKKQVEKALKQLEDKVQ).
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atoms (C8) {-HN-CH[(CH2)5CH3]-OH}, which was followed sequentially by the
coupling of Boc-Gly-OH, Boc-C8-OH, and Boc-Lys(Boc)-OH. Thus, the li-
pophilic anchor was constructed by using three copies of racemic 2-amino-
octanoic lipoamino acids. After deprotection of the lysine  and ε amino groups,
a four-branch system was formed by coupling of Fmoc (9-fluorenyl methoxy
carbonyl)-Lys(Boc)-OH to the free amino groups. The Boc-protecting groups
were removed, and two identical 8830 peptide sequences were coupled directly
onto the branched lysine core, with the appropriate protecting groups applied on
the side chains of the amino acids. After synthesis of the two copies of the 8830
GAS peptide was completed, the Boc-protecting groups were removed and the
free N-terminal groups were acetylated with a mixture of 2.5 mmol of acetic
anhydride and 2.5 mmol of diisopropylethylamine in dimethylformamide, result-
ing in the (acetyl-8830 peptide)2 (Fmoc)2 (ALys)2ALys-C8-Gly-C8-C8-Gly-
MBHA resin. After removal of the Fmoc-protecting groups by mixing the pep-
tide-resin in 20% piperidine in DMF for 20 min, the J8 GAS peptide was
assembled on each of the two new branches, with the appropriate protecting
groups applied on the side chains of the amino acids. The chemical structure of
the LCP-8830-J8 formulation is shown in Fig. 1. Sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis (SDS-PAGE) resulted in bands of the expected
sizes for LCP-GAS. The mass spectrum of LCP-8830-J8 was calculated as
12,373.11 Da.
Mice and immunization. All protocols were approved by the Bancroft Centre
Research Ethics Committee and were carried out according to Australian Na-
tional Health and Medical Research guidelines. Four- to 6-week-old female
B10.BR mice (Animal Resource Centre, Perth, Western Australia, Australia)
were used (n  10 per group) in two separate experiments for subcutaneous
immunization at the tail base on day 0 with 30 g of LCP-GAS, either emulsified
1:1 with CFA (Sigma) (LCP-GAS–CFA) or given alone in a total volume of 50
l of sterile-filtered phosphate-buffered saline (PBS) (LCP-GAS–PBS). After 3
weeks, mice received five further boosts at weekly intervals (days 21, 28, 35, 42,
and 49) with 3 g of LCP-GAS–PBS prior to collection of blood. Controls
received either 30 g of the 8830 or the J8 GAS peptide in CFA with boosts of
3 g in PBS or CFA-PBS alone.
Collection of sera. Blood was collected 1 week after the last immunization (day
56) from each mouse by the tail artery and was allowed to clot at 37°C for 1 h,
followed by removal of clots by centrifugation at 3,000 rpm for 10 min. Sera were
then stored at 20°C.
ELISA. An enzyme-linked immunosorbent assay (ELISA) was performed for
measurement of total immunoglobulin G (IgG) antibody titers in sera, essentially
as described previously (37). Serum samples were assayed by using twofold
dilutions of a 1:100 dilution of serum. For IgG isotyping, horseradish peroxidase-
conjugated sheep anti-mouse IgG1, IgG2a, IgG2b, and IgG3 antibodies (The
Binding Site, Birmingham, United Kingdom) were used as the secondary anti-
bodies. Antibody titers were defined as the lowest dilution that gave an optical
density (OD) reading at 450 nm of more than 3 standard deviations above the
mean OD of control wells containing normal mouse sera (obtained from mice
immunized with CFA in PBS).
Bactericidal assay. Serum opsonic antibodies against the 8830 and M1 GAS
strains were detected by a standard bactericidal assay, as described previously
(37). Briefly, GAS were incubated end over end at 37°C for 3 h in the presence
of nonopsonic human donor blood and either heat-inactivated (60°C for 10 min)
mouse immune serum or control normal mouse serum. GAS were then plated in
duplicate on 2% (vol/vol) horse blood agar plates, and colonies were counted
after 24 h of incubation. The percentage of GAS opsonized was determined by
counting the number of colonies growing after incubation with test immune
serum and comparing this with the number of colonies growing after incubation
with control serum. Opsonic activity (percent reduction in mean CFU) was
calculated as (1  CFU in the presence of immune serum)/(mean CFU in the
presence of normal mouse serum)  100.
Peptide inhibition bactericidal assay. The peptide inhibition bactericidal assay
was performed essentially as described above except that sera were initially
incubated for 30 min at room temperature with 100 g of peptide prior to
incubation with GAS and nonopsonic donor blood. Peptides used were the 8830
GAS peptide, the J8 GAS peptide, and a nonspecific control peptide from a
Schistosoma sp. (EGKVSTLPLDIQIIAATMSK). The percent inhibition of op-
sonization was calculated as (CFU in immune sera with peptide  CFU in
immune sera with no peptide)/(CFU in normal mouse sera with no peptide 
CFU in immune sera with no peptide)  100.
Western blot analysis. Mouse LCP-8830-J8 antisera were tested for cross-
reactivity to four different human heart preparations (two heart and two mitral
valve extracts) obtained from patients undergoing heart transplant surgery at
The Prince Charles Hospital (with ethics approval from The Prince Charles
Hospital Foundation), porcine heart myosin (Sigma), and porcine muscle tro-
pomyosin (Sigma) by standard SDS-PAGE and Western blot analysis (37). The
J8 GAS peptide was conjugated to diptheria toxoid and included as a positive
control. Prestained kaleidoscope protein size markers were used (Bio-Rad, Her-
cules, Calif.). Briefly, 5 g of each protein was electrophoresed on two commer-
cially available precast 4 to 20% Gradigels (Gradipore); one gel was stained with
Coomassie blue and destained in 40% methanol–10% acetic acid, and the second
gel was blotted onto a PVDF-Plus transfer membrane (Micron Separations Inc.,
Westborough, Mass.) according to the manufacturer’s instructions. The anti-
serum was used as the primary antibody at a dilution of 1:1,500, and the sec-
ondary sheep anti-mouse IgG antibody (Silenus Pty Ltd., Melbourne, Victoria,
Australia) was used at a dilution of 1:1,500.
Growth of GAS and intraperitoneal challenge. GAS strain 8830 (obtained
from clinical isolates in the Northern Territory of Australia and verified by M
protein N-terminal sequencing) which had been serially passaged in mouse
spleens to enhance virulence was used in the challenge experiments. The GAS
strain was cultured overnight at 37°C in Todd-Hewitt broth (THB)–1% neopep-
tone. Bacteria were collected by centrifugation for 10 min at 3,000 rpm (Beck-
man model 9S-6R centrifuge) and washed twice with THB–1% neopeptone prior
to resuspension in 25% of the original volume. Bacteria were then serially 10-fold
diluted in broth and plated onto 2% blood–TH agar plates in order to estimate
the inoculum size (in CFU per milliliter) after overnight incubation at 37°C. Two
weeks after the last boost (day 63), mice were challenged intraperitoneally with
400 l (1  105 CFU/ml in experiment 1; 2.5  104 CFU/ml in experiment 2) of
GAS 8830. The dose of GAS had previously been shown to kill approximately
90% of naive animals. According to Institutional Ethics Committee require-
ments, mice that were found to be moribund were euthanized.
Statistical analysis. The Wilcoxon rank sum statistic was used for comparison
of antibody titers and percent opsonization levels in the different groups. SPSS,
release 10.0, was used for statistical analysis. Fisher’s exact test was used to
compare the proportions of surviving mice in the different experimental groups.
For survival analysis (time to death), the log rank test was used to compare the
differences in survival times in the different groups. Resulting P values below 0.05
were taken to indicate statistically significant differences.
RESULTS
Serum IgG antibody responses in B10.BR mice immunized
with LCP-8830-J8. To assess the immunogenicity of the LCP-
8830-J8 formulation, which contains an M protein amino-ter-
minal type-specific peptide sequence (8830) in combination
with a conserved non-host-cross-reactive carboxy-terminal C-
region peptide sequence (J8) of the M protein (Fig. 1), serum
IgG antibody responses to GAS peptides 8830 and J8 were
determined for mice immunized with LCP-GAS, either with
(LCP-GAS–CFA) or without (LCP-GAS–PBS) CFA, in a du-
plicate experiment (Fig. 2). In both experiments, in which mice
were to be challenged with GAS strain 8830, the 8830 GAS
peptide was coadministered in CFA as a positive control. A J8
GAS peptide-CFA-immunized control group was included in
experiment 1. Three weeks after the primary immunization,
8830 and J8 GAS peptide-specific antibodies were detected in
all mice immunized with LCP-GAS–CFA, giving final average
titers of antibodies to the 8830 and J8 GAS peptides, after five
boosts, of 2.18  106 and 2.55  106, respectively (experiment
1; Fig. 2A and B). No antibodies specific to the 8830 and J8
GAS peptides were detected at 3 weeks postimmunization in
mice immunized with LCP-GAS–PBS. However, after one
boost of immunogen, 8 of the 10 mice had 8830 GAS peptide-
specific antibodies and 3 mice had J8 GAS peptide-specific
antibodies. After the third boost of immunogen, antibodies to
the 8830 GAS peptide were detected in all mice and eight of
the mice demonstrated a response to the J8 peptide. After the
final boost (boost 5), the average 8830 and J8 GAS peptide-
specific antibody titers in mice immunized with LCP-GAS–
PBS were 1.04  105 and 6.91  103 (experiment 1), respec-
tively.
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In the second experiment (Fig. 2C and D), in which mice
also received a primary immunization and five boosts each of
the same immunogen, the final average 8830 and J8 GAS
peptide-specific serum IgG antibody titers were 2.29 106 and
6.34  104, respectively, for mice immunized with LCP-GAS–
CFA. For mice immunized with LCP-GAS–PBS, the average
titers of antibody to the 8830 and J8 GAS peptides were 1.39
106 and 1.80  103, respectively. For 8830 GAS peptide-CFA-
immunized control mice, average 8830 peptide-specific serum
IgG antibody titers were 1.97  106 (experiment 1) and 2.38 
106 (experiment 2). While immunization with LCP-GAS–CFA
produced antibody responses to the 8830 peptide similar to
those of the control group given monomeric 8830 peptide
alone in CFA, the response to the J8 peptide was substantially
higher than that of mice administered J8 peptide alone in CFA
(P  0.0001) (Fig. 2B). We observed that the immunogenicity
of LCP-GAS for the J8 peptide was lower in experiment 2 than
in experiment 1 (titers, 6.34  104 versus 2.55  106 in CFA;
1.80  103 versus 6.91  103 in PBS) (Fig. 2B and D). The
possibility of antigen degradation during storage of the vaccine
was not an issue, because the immunogenicity of LCP-GAS
after 8 months’ storage yielded final average J8 GAS peptide-
specific serum IgG antibody titers of 2.46 106 and 6.68 104
in LCP-GAS–CFA- and LCP-GAS–PBS-immunized mice, re-
spectively (data not shown); these were comparable to the
titers obtained in experiment 1 after storage for 1 month.
Overall, the antibody responses to the 8830 GAS peptide
were not significantly different following immunization with
LCP-GAS–CFA or 8830 GAS peptide-CFA. Antibody re-
sponses to the J8 GAS peptide, however, were significantly
elevated in LCP-GAS–CFA-immunized mice relative to those
in the J8 GAS peptide-CFA-immunized group. In mice immu-
nized with LCP-GAS–PBS, the antibody responses to both the
8830 and J8 GAS peptides were generally lower than those in
the LCP-GAS–CFA and peptide-CFA groups, although some
mice exhibited particularly high-titer antibody responses to the
FIG. 2. Serum IgG antibody responses in B10.BR mice immunized parenterally with the LCP-8830-J8 (LCP-GAS) formulation in the presence
(LCP-GAS–CFA) or absence (LCP-GAS–PBS) of CFA, for experiment 1 (A and B) and experiment 2 (C and D). Antibody titers to the 8830 and
J8 GAS peptides for individual mice are shown, with the average titer (geometric mean) indicated by a bar. Antibody titers to the 8830 and J8
peptides are shown for individual control mice that were immunized with the 8830 peptide in CFA or the J8 peptide in CFA, respectively. By use
of the Wilcoxon rank sum statistic, mean antibody titers were significantly different in the different immunized groups: *, P  0.0001; **, P 
0.0001; ***, P  0.0001; ****, P  0.0001; *****, P  0.002; ******, P  0.001.
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8830 peptide (Fig. 2C). It should be emphasized that CFA is
considered the “gold standard” adjuvant in that it induces
exceptionally high immune responses.
Serum IgG isotype antibody response in B10.BR mice im-
munized with LCP-8830-J8. To investigate further the nature
of the peptide-specific serum IgG antibody response induced
following parenteral delivery of LCP-GAS, we assessed the
IgG subclass types that were elicited by the 8830 and J8 GAS
peptides (Tables 1 and 2). In LCP-GAS–CFA-immunized
mice, high titers of 8830 and J8 peptide-specific IgG1, IgG2a,
and IgG2b antibodies were detected in the majority of mice,
with lower titers detected for IgG3. Similarly, control mice
immunized with monomeric peptide (8830) in CFA, or J8 in
CFA, also showed high titers of IgG1, IgG2a, and IgG2b an-
tibodies, with lower IgG3 antibody titers. For mice immunized
with LCP-GAS–PBS, there was a preponderance of 8830 pep-
tide-specific IgG1 antibodies elicited, whereas titers of 8830
peptide-specific IgG2a, IgG2b, and IgG3 antibodies were
lower than those for mice immunized with LCP-GAS–CFA or
8830 peptide-CFA. The lower antibody titers most likely re-
flect the lower 8830 peptide-specific serum IgG antibody titers
detected for this group relative to those for mice immunized
with LCP-GAS–CFA (1.04  105 versus 2.18  106 in exper-
iment 1; 1.39  106 versus 2.29  106 in experiment 2). The
serum IgG antibody response to the J8 peptide in LCP-GAS–
PBS-immunized mice showed a preponderance of IgG1 in
experiment 2. However, very little J8 peptide-specific antibody
of any IgG isotype was detected in experiment 1. This is most
likely due to the lower titers of J8 peptide-specific IgG anti-
bodies detected in the sera of LCP-GAS–PBS-immunized mice
relative to those in mice immunized with LCP-GAS–CFA (av-
erages, 6.91  103 versus 2.55  106 in experiment 1; 1.80 
103 versus 6.34  104 in experiment 2).
Overall, the IgG isotype responses to the 8830 and J8 GAS
peptides were similar following immunization with LCP-GAS–
CFA or peptide-CFA, with the general trend of higher pep-
tide-specific IgG1, IgG2a, and IgG2b antibodies and lower
peptide-specific IgG3 antibodies. In mice immunized with
LCP-GAS–PBS, antibody responses to the 8830 peptide were
highest for IgG1, with IgG2b, IgG2a, and IgG3 following in
that order, whereas a predominantly IgG1 response to J8 pep-
tide was observed, with few mice giving an IgG2a or IgG2b
response.
Induction of opsonic antibodies in B10.BR mice immunized
with LCP-8830-J8. Using an indirect bactericidal assay, we
assessed the opsonic activity toward GAS strain 8830 of serum
TABLE 1. Serum 8830-specific IgG isotype antibody responses in B10.BR mice immunized parenterally with LCP-8830-J8–CFA,
LCP-8830-J8, or 8830-CFA
Immunogen Mouse
Titera of:
IgG1 IgG2a IgG2b IgG3
Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2
LCP-8830-J8–CFA M1 12,800 12,800 12,800 12,800 12,800 12,800 3,200 0
M2 12,800 12,800 12,800 12,800 12,800 12,800 3,200 1,600
M3 12,800 12,800 12,800 12,800 12,800 12,800 3,200 200
M4 12,800 12,800 12,800 6,400 12,800 12,800 3,200 1,600
M5 12,800 12,800 12,800 6,400 12,800 12,800 3,200 200
M6 12,800 12,800 12,800 12,800 12,800 12,800 12,800 200
M7b 12,800 12,800 12,800 200
M8 12,800 12,800 12,800 12,800 12,800 12,800 3,200 1,600
M9 12,800 12,800 12,800 3,200 12,800 12,800 3,200 200
M10 12,800 12,800 12,800 12,800 12,800 12,800 3,200 12,800
LCP-8830-J8 M1 12,800 12,800 3,200 0 3,200 12,800 400 0
M2 12,800 12,800 3,200 6,400 200 12,800 100 0
M3 100 12,800 0 0 0 3,200 0 0
M4 12,800 12,800 3,200 0 3,200 400 400 0
M5 12,800 12,800 3,200 1,600 12,800 12,800 800 0
M6b 12,800 3,200 6,400 400
M7 12,800 12,800 100 200 200 200 0 0
M8 12,800 12,800 800 0 3,200 0 200 0
M9 12,800 12,800 800 0 200 400 100 0
M10 200 12,800 0 0 0 0 0 0
8830-CFA M1 12,800 12,800 12,800 12,800 12,800 12,800 1,600 100
M2 12,800 12,800 12,800 12,800 12,800 12,800 1,600 100
M3 12,800 12,800 12,800 12,800 12,800 12,800 3,200 100
M4 12,800 12,800 12,800 12,800 12,800 12,800 3,200 100
M5 12,800 12,800 12,800 12,800 12,800 12,800 3,200 200
M6 12,800 12,800 12,800 12,800 12,800 12,800 3,200 200
M7 12,800 12,800 12,800 12,800 12,800 12,800 3,200 100
M8 12,800 12,800 12,800 12,800 12,800 12,800 3,200 200
M9 6,400 12,800 12,800 12,800 12,800 12,800 3,200 100
M10 12,800 12,800 12,800 12,800 12,800 12,800 3,200 1,600
a IgG1, IgG2a, IgG2b, and IgG3 titers are shown for individual mice for experiments 1 and 2.
b Mouse 7 (LCP-GAS–CFA group, experiment 1) and mouse 6 (LCP-GAS—PBS group, experiment 2) died prior to analysis.
VOL. 71, 2003 LIPID CORE PEPTIDE TECHNOLOGY IN VACCINE DELIVERY 2377
 o
n
 O
ctober 20, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
IgG antibodies elicited after parenteral delivery of LCP-
8830-J8 (Fig. 3A and C; Table 3). The average percent opso-
nization of GAS 8830 by LCP-GAS–CFA antisera was 96%
(82% for LCP-GAS–PBS) for experiment 1 and 93% (68% for
LCP-GAS–PBS) for experiment 2. There was complete opso-
nization of GAS by control 8830 peptide-CFA antisera in ex-
periment 1 and 93% opsonization by control antisera in exper-
iment 2. We also assessed the potential of antisera generated
in experiment 1 for opsonizing another GAS strain, M1 (Fig.
3B and Table 3). Unlike the relatively low opsonization of
GAS by antibodies induced to the C-region J8 peptide epitope
(23%) following immunization with J8 peptide-CFA, positive-
control antisera against pepM1 (the amino-terminal half of M1
protein) completely opsonized GAS M1. The average percent
opsonization for LCP-GAS–CFA antisera against GAS M1
was 67% (48% for LCP-GAS–PBS). There was a low level of
opsonization (10%) for 8830 peptide-CFA antisera against the
heterologous GAS M1 strain, demonstrating a lack of cross-
reactivity between type-specific M protein determinants. These
findings indicate that opsonization of GAS M1 by LCP-GAS
antisera was mediated partly by antibodies directed against the
J8 conserved C-region peptide epitope on GAS.
To confirm the specificity of the serum opsonic antibodies
induced in LCP-GAS-immunized mice, a peptide inhibition
bactericidal assay was performed which involved preincubation
of immune sera with either the 8830 peptide, the J8 peptide, or
a nonspecific control peptide derived from Schistosoma prior
to assessment of opsonization. The percent inhibition of opso-
nization was then determined by comparing the percentage of
opsonization in the presence of the peptide to that observed in
the absence of the peptide. Opsonization of GAS 8830 by
pooled LCP-GAS–CFA or LCP-GAS–PBS antisera in the ab-
sence of peptide was 100 or 95%, respectively. Preincubation
of LCP-GAS–CFA antisera with the 8830 peptide, however,
led to almost complete inhibition (89%) of opsonization. LCP-
GAS antisera preincubated with the 8830 peptide showed 78%
inhibition of opsonization. The nonspecific peptide and the J8
peptide did not inhibit the opsonization of GAS 8830 by LCP-
GAS–CFA and LCP-GAS antisera.
Together, these data indicate that the LCP-8830-J8 formu-
lation induced serum opsonic antibodies specifically directed
against the M protein type-specific peptide epitope on GAS
strain 8830.
Lack of heart-cross-reactive antibodies. The GAS M protein
(12), by virtue of its homology with various structural heart
antigens, may mediate autoimmune responses and play a role
in the pathogenesis of RHD. It was therefore necessary to
assess whether heart-cross-reactive antibodies were elicited in
TABLE 2. Serum J8-specific IgG isotype antibody responses in B10.BR mice immunized parenterally with LCP-8830-J8–CFA,
LCP-8830-J8, or J8-CFA
Immunogen Mouse
Titera of:
IgG1 IgG2a IgG2b IgG3
Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2
LCP-8830-J8–CFA M1 12,800 12,800 3,200 3,200 12,800 12,800 3,200 0
M2 12,800 12,800 3,200 800 12,800 3,200 1,600 0
M3 12,800 12,800 3,200 6,400 12,800 12,800 1,600 0
M4 12,800 12,800 6,400 3,200 12,800 12,800 1,600 0
M5 12,800 12,800 3,200 12,800 12,800 3,200 1,600 0
M6 12,800 12,800 6,400 12,800 12,800 12,800 3,200 100
M7b 12,800 3,200 12,800 0
M8 12,800 12,800 3,200 0 12,800 3,200 1,600 0
M9 12,800 12,800 6,400 12,800 12,800 12,800 1,600 100
M10 12,800 12,800 3,200 12,800 12,800 12,800 1,600 100
LCP-8830-J8 M1 3,200 12,800 3,200 0 400 0 0 0
M2 400 12,800 100 0 0 0 0 0
M3 0 3,200 0 0 0 0 0 0
M4 0 12,800 100 100 0 12,800 0 0
M5 100 12,800 100 0 100 100 0 0
M6b 100 0 0 0
M7 0 800 0 0 0 0 0 0
M8 3,200 3,200 800 0 400 0 0 0
M9 0 12,800 0 0 0 12,800 0 0
M10 0 3,200 0 0 0 100 0 0
J8–CFA M1 12,800 3,200 6,400 400
M2 12,800 12,800 6,400 800
M3 12,800 320 1,600 400
M4 1,600 3,200 3,200 400
M5 12,800 3,200 1,600 400
M6 1,600 12,800 3,200 400
M7 12,800 12,800 6,400 800
M8 12,800 12,800 3,200 800
M9 12,800 3,200 1,600 400
M10a
a IgG1, IgG2a, IgG2b, and IgG3 titers are shown for individual mice for experiments 1 and 2.
b Mouse 7 (LCP-GAS–CFA group, experiment 1), mouse 6 (LCP-GAS–PBS group, experiment 2), and mouse 10 (J8-CFA group) died prior to analysis.
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response to immunization with the LCP-8830-J8 formulation.
Sera from mice immunized parenterally with LCP-8830-J8
were tested for the presence of cross-reactive antibodies to
human heart and mitral valve extracts by use of standard SDS-
PAGE and Western blot analysis. J8 conjugated to diptheria
toxoid was included as a positive control and was recognized
strongly by LCP-8830-J8 antisera. No reactivity, however, was
observed to any of the heart tissue proteins (data not shown).
Survival of mice immunized with LCP-8830-J8 and chal-
lenged with GAS. To determine whether immunization of mice
with LCP-GAS, which induced production of serum opsonic
antibodies, also induced protective immunity to GAS, mice
were challenged in vivo with GAS strain 8830 (105 and 2.5 
104 CFU/ml for experiments 1 and 2, respectively) and the
percent survival was determined up to 10 days postchallenge.
Compared to the CFA-PBS control group, in which 11% of the
mice (1 of 9) survived, the percent survival of mice immunized
with LCP-GAS–CFA was 90% (8 of 9) (P  0.003) (Fig. 4).
There was complete protection of mice (10 of 10) immunized
with LCP-GAS–PBS (P  0.0001 versus the CFA-PBS group).
Survival was 90% (9 of 10) in 8830 peptide-CFA-immunized
mice (P  0.001 for comparison to CFA-PBS control mice).
Analysis of the survival times of these groups compared to
those for CFA-PBS control mice also showed significantly in-
creased survival for mice immunized with LCP-GAS–CFA
(P  0.0013), LCP-GAS–PBS (P  0.0001), or 8830 peptide-
CFA (P  0.0008). In experiment 2, compared to the CFA-
PBS control group, in which 50% (5 of 10) of mice survived,
the percent survival of mice immunized with LCP-GAS–CFA
was 100% (10 of 10) (P  0.033) (Fig. 4). There was complete
protection of mice (9 of 9) immunized with LCP-GAS–PBS
(P  0.033). Survival was 100% (10 of 10) in 8830 peptide-
CFA-immunized mice (P  0.033 for comparison to the CFA-
PBS group). Analysis of the survival times for these groups
compared to those for CFA-PBS control mice also showed
significantly increased survival for mice immunized with LCP-
GAS–CFA (P  0.011), LCP-GAS–PBS (P  0.017), or 8830
peptide-CFA (P 0.011). In experiment 2, two groups of mice
were also immunized with an LCP formulation containing four
copies of a control peptide from Schistosoma (referred to as
LCP-SP) in the presence or absence of CFA. Survival in these
groups was 55% (5 of 9) and 44% (4 of 9) for LCP-SP–CFA-
and LCP-SP–PBS-immunized mice, respectively, and was not
significantly different from that for control CFA-PBS-immu-
nized mice. Analysis of the survival times for these groups
compared to those for CFA-PBS control mice also showed no
significant differences.
DISCUSSION
Development of synthetic peptide-based immunogens is
emerging as a possible approach for human vaccination in the
future, as indicated particularly by recent reports of experi-
FIG. 3. Opsonization of GAS strains 8830 and M1 by LCP-GAS–
CFA, LCP-GAS–PBS, and control (8830 peptide-CFA or J8 peptide-
CFA) B10.BR mouse antisera in experiments 1 (A and B) and 2 (C).
The average percent opsonization (measured as the percent reduction
in CFU of bacteria) for each individual group is shown. Error bars,
standard errors of the means. Opsonization was determined by an
indirect bactericidal assay which compares the growth of bacteria (ex-
pressed in CFU) following incubation in the presence of immune sera
to that with control normal mouse sera obtained from mice immunized
with adjuvant in PBS alone. By use of the Wilcoxon rank sum statistic,
mean opsonization levels for the different immunized groups were
significantly different: *, P 0.036; **, P 0.004; ***, P 0.002; ****,
P  0.037; *****, P  0.041.
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mental models demonstrating the potential of synthetic poly-
meric (22), linear and nonlinear (branched) B-cell-T-cell (14,
16), and synthetic lipid-containing peptide immunogens (1, 11,
24, 27–31, 39, 40, 45–48; reviewed in reference 2) as alterna-
tives to conventional vaccine delivery. In this study we report
on the synthesis, immunogenicity, and protective potential of a
novel LCP-GAS vaccine candidate incorporating two different
M protein protective peptide epitopes. The -helical coiled-
coil M protein consists of a highly variable amino-terminal
region, which defines the GAS serotype, and a highly con-
served C region (12) and remains the major candidate in vac-
cination against GAS infection. Development of a broad-
strain-coverage, M protein-based GAS vaccine has proven
difficult due to the sequence variability of different M proteins
(more than 100 serotypes are known) and the potential for
induction of autoimmunity due to antigenic molecular mimicry
with self antigen (15). Our data have shown that immunization
of mice with an LCP-GAS formulation (LCP-8830-J8) contain-
ing an M protein type-specific amino-terminal peptide se-
quence (8830) and a non-host-cross-reactive carboxy-terminal
conserved C-region peptide sequence (J8) elicited high-titer
serum IgG antibodies to both the 8830 and J8 GAS peptides in
the presence and absence of CFA and that this formulation did
not induce antibodies to cross-react with human heart tissue
proteins. The peptide-specific serum IgG antibody subtypes
induced were predominantly IgG1, IgG2a, and IgG2b for LCP-
GAS–CFA-immunized mice and predominantly IgG1 for mice
immunized with LCP-GAS–PBS, thus favoring Th2 responses.
It remains to be determined whether the LCP system could be
combined with other, more Th1 adjuvants to further increase
the potential usefulness of this delivery system.
Using an indirect bactericidal assay, we have further dem-
onstrated induction of opsonic antibodies to two different GAS
strains, 8830 and M1, following immunization with LCP-8830-
J8, again in the presence or absence of CFA. The opsonization
of GAS strains 8830 and M1 by LCP-GAS–CFA and LCP-
GAS–PBS antisera indicates that serum opsonic antibodies to
the type-specific amino-terminal and conserved C-regions of
the M protein were induced in mice following immunization
with LCP-GAS. Moreover, induction of opsonic antibodies
was not dependent on the presence of conventional adjuvant,
as demonstrated by opsonization of GAS strains 8830 and M1
by antisera from LCP-GAS–PBS-immunized mice, supporting
the efficacy of the LCP system as a self-adjuvanting vaccine
delivery modality. The ability of the 8830 GAS peptide to
inhibit opsonization of GAS strain 8830 by LCP-GAS–CFA
and LCP-GAS–PBS antisera indicates that the LCP-GAS for-
mulation induced serum opsonic antibodies specifically di-
rected against the M protein type-specific peptide epitope on
GAS and may potentially be important in protective immunity
to GAS infection. The inability of the J8 peptide to inhibit the
opsonization of GAS 8830 indicates that opsonic antibodies
generated to the C region of the M protein are not necessary
for the opsonization of GAS 8830 in the presence of type-
specific opsonic antibodies. We have recently shown, however,
that an LCP compound comprised solely of J8 induced serum
J8-specific heterologous opsonic antibodies (31) which may be
involved in mediating broadly protective immune responses.
Upon challenge of mice with GAS strain 8830 in two sepa-
rate experiments, animals were completely protected from
GAS infection. These results indicate that immunization with
LCP-GAS induced type-specific opsonic antibodies that are
important for protective immunity to GAS, and they support
our earlier findings and those of others demonstrating the
efficacy of the LCP system as a vaccine delivery approach for
enhancing the immunogenicity of various synthetic peptide
immunogens (31, 46, 48) including viral and bacterially derived
antigens. It is noteworthy that while serum IgG responses and
opsonic antibodies induced in response to LCP-GAS–CFA
were greater than those with LCP-GAS given in the absence of
adjuvant, equivalent levels of survival were attained. This may
indicate that sufficient levels of antibody were elicited for pro-
tection or that additional factors may contribute to the protec-
tive mechanisms involved.
Previous strategies to develop a broad-strain-coverage GAS
vaccine have included the design of recombinant multivalent
M protein vaccine constructs containing epitopes from the
amino-terminal type-specific regions of several different M
protein serotypes (6, 10, 21) and the identification of vaccine
candidates based on the conserved C region of the M protein
(6, 8, 31, 32). Peptide J8 has been identified as the minimal
murine protective B-cell epitope in the M protein C region
TABLE 3. Opsonization of GAS by LCP-GAS and control antiseraa
GAS strain
No. of bacteria in
GAS inoculum
(CFU)
No. of bacteria in
normal mouse serum
(mean CFU)
Immunogen
No. of bacteria in
immune serum
(mean CFU)
% Average
population
reduction
8830 (expt 1) 62 84,004 LCP-GAS–CFA 3,251 96
LCP-GAS–PBS 15,004 82
8830–CFA 132 100
M1 107 35,724 LCP-GAS–CFA 11,937 67
LCP-GAS–PBS 18,590 48
J8-CFA 27,675 23
pepM1-CFA 2 100
8830-CFA 34,890 2
8830 (expt 2) 76 450,750 LCP-GAS–CFA 31,529 93
LCP-GAS–PBS 132,792 68
8830–CFA 31,024 93
a By use of an indirect bactericidal assay and GAS strains 8830 and M1, mean bacterial-population counts (in CFU) from individual serum samples plated out in
duplicate were determined following incubation of GAS of a known inoculum size in the presence of immune sera (LCP-GAS–CFA, LCP-GAS–PBS, 8830-CFA,
J8-CFA, or pepM1-CFA) and of control normal mouse sera obtained from mice immunized with CFA in PBS alone. Average percentages of bacterial-population
reduction were determined by comparing the mean CFU in immune sera to those in control sera.
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FIG. 4. Survival curves for mice immunized with LCP-GAS–CFA, LCP-GAS–PBS, and control 8830 peptide-CFA following parenteral GAS
challenge in two separate experiments. By use of Fisher’s exact test to compare the proportions of surviving mice, significantly greater survival was
observed for mice immunized with LCP-GAS–CFA or LCP-GAS–PBS than for control CFA-PBS-immunized mice (P  0.003 and P  0.0001,
respectively, for experiment 1; P  0.033 for experiment 2).
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(19). It has recently been reported that the J8 peptide signifi-
cantly protected mice against GAS infection following mucosal
immunization and challenge (32). The vaccine required conju-
gation to diphtheria toxoid and was delivered in the presence
of the mucosal adjuvant, cholera toxin B subunit. Other ap-
proaches which have been used for delivery of recombinant M
proteins have involved their expression on commensal bacteria
such as attenuated Salmonella enterica serovar Typhimurium
(34) or Streptococcus gordonii (35) or on live viral vectors such
as vaccinia virus (13). There are obvious safety concerns, how-
ever, associated with using pathogenic organisms as live vac-
cine vector delivery systems.
Dale and colleagues have developed recombinant 8- and
26-valent M protein vaccine constructs containing epitopes
from the amino-terminal regions of different M protein sero-
types (10, 21). In each case, the vaccines were shown to be
immunogenic in rabbits. Furthermore, the antisera produced
were opsonic against the GAS strains represented in the re-
combinant constructs, and there was no cross-reactivity with
human tissues, indicating the potential use of these vaccines in
inducing safe and protective immune responses. Theoretically,
however, these vaccines would provide protection only against
the GAS strains represented in the constructs. The design of a
multiepitope GAS vaccine construct, referred to as “hetero-
polymer,” targeted specifically to GAS strains commonly iso-
lated from patients in the Australian aboriginal population of
the Northern Territory, has recently been reported (6). The
construct is essentially a random polymer and contains multi-
ple M protein amino-terminal peptides and a conserved C-
region peptide. Mice were completely protected following
parenteral immunization with heteropolymer in CFA and
challenge with two different GAS strains (6).
Although the autoimmunity consequences of these vaccines
have potentially been eliminated, together these strategies are
fraught with problems of strain variability, quality control (in
the case of the heteropolymer, with its lack of defined order of
peptides), and adjuvant toxicity that need to be overcome
before progression to clinical trials.
This report indicates the potential of LCP technology as a
safe and effective alternative approach to the delivery of new-
generation synthetic peptide vaccines containing different pro-
tective epitopes of either the same or different target antigens.
For example, the recently identified protective epitope of SfbI,
an adhesin important in the colonization of human epithelial
cells and in imparting protective immunity to GAS (42), could
be combined with an M protein protective epitope in the de-
sign of a multivalent LCP-based GAS vaccine. Due to the
self-adjuvanting properties of the LCP system, LCP-based vac-
cines may also have the potential for mucosal delivery of nasal
vaccines against many human mucosal pathogens. Moreover,
due to the defined order of unique sequences on the lipid core
within the vaccines, quality control of the products is assured.
Together our findings indicate the potential of the LCP
system in the delivery of self-adjuvanting multi-antigen com-
ponent synthetic peptide vaccines, with a view to the develop-
ment of mucosa-based vaccines for human vaccination.
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